Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

The Lancet Oncology

Volumn 19, Issue 2, 2018, Pages 216-228

  DiNardo, Courtney D ^a   Pratz, Keith W ^b   Letai, Anthony ^c   Jonas, Brian A ^d   Wei, Andrew H ^e   Thirman, Michael ^f   Arellano, Martha ^g   Frattini, Mark G ^h   Kantarjian, Hagop ^a   Popovic, Relja ⁱ   Chyla, Brenda ⁱ   Xu, Tu ⁱ   Dunbar, Martin ⁱ   Agarwal, Suresh K ⁱ   Humerickhouse, Rod ⁱ   Mabry, Mack ⁱ   Potluri, Jalaja ⁱ   Konopleva, Marina ^a   Pollyea, Daniel A ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NewYork Presbyterian Hospital   (United States)

ⁱ ABBVIE INC   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZACITIDINE; BILIRUBIN; CD135 ANTIGEN; DECITABINE; POSACONAZOLE; VENETOCLAX; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ACUTE MYELOID LEUKEMIA; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CANDIDIASIS; CAUSE OF DEATH; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLT3 GENE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HUMAN; HYPERPHOSPHATEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PRURITUS; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; GERIATRIC ASSESSMENT; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MORTALITY; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PROCEDURES; PROGNOSIS; REMISSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CONFIDENCE INTERVALS; DECITABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MAXIMUM TOLERATED DOSE; PATIENT SAFETY; PROGNOSIS; REMISSION INDUCTION; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85042766499     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30010-X     Document Type: Article

References (24)

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: acute myeloid leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html (accessed May 30, 2017).
2. Krug, U, Büchner, T, Berdel, WE, Müller-Tidow, C, The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int 108 (2011), 863–870.
3. Pettit, K, Odenike, O, Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies. Front Oncol, 5, 2015, 280.
4. Kantarjian, H, Ravandi, F, O'Brien, S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116 (2010), 4422–4429.
5. Kantarjian, H, O'Brien, S, Cortes, J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106 (2006), 1090–1098.
6. Lagadinou, ED, Sach, A, Callahan, K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12 (2013), 329–341.
7. Pan, R, Ruvolo, VR, Wei, J, et al. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood 126 (2015), 363–372.
8. Pan, R, Hogdal, LJ, Benito, JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4 (2014), 362–375.
9. Konopleva, M, Pollyea, DA, Potluri, J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6 (2016), 1106–1117.
10. Bogenberger, JM, Delman, D, Hansen, N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56 (2015), 226–229.
11. Tsao, T, Shi, Y, Kornblau, S, et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 91 (2012), 1861–1870.
12. Bose, P, Gandhi, V, Konopleva, M, Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma 31 (2017), 1–17.
13. Vardiman, JW, Thiele, J, Arber, DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114 (2009), 937–951.
14. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines). Acute myeloid leukemia version 2.2014. http://williams.medicine.wisc.edu/aml.pdf (accessed May 30, 2017).
15. Agarwal, SK, DiNardo, CD, Potluri, J, et al. Management of venetoclax–posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther 39 (2017), 359–367.
16. Cheson, BD, Bennett, JM, Kopecky, KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21 (2003), 4642–4649.
17. Murphy, KM, Levis, M, Hafez, MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 5 (2003), 96–102.
18. Konopleva, M, Pollyea, DA, Potluri, J, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood, 124, 2014, 118.
19. Salem, AH, Agarwal, SK, Dunbar, M, Enschede, SL, Humerickhouse, RA, Wong, SL, Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol 57 (2017), 484–492.
20. Roberts, AW, Davids, MS, Pagel, JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374 (2016), 311–322.
21. Kantarjian, HM, Thomas, XG, Dmoszynska, A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30 (2012), 2670–2677.
22. Dombret, H, Seymour, JF, Butrym, A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126 (2015), 291–299.
23. Cornely, OA, Maertens, J, Winston, DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007), 348–359.
24. Chan, SM, Thomas, D, Corces-Zimmerman, MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21 (2015), 178–184.